Barbara Melotti

Bologna, 40138, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 87 publications

Thin Nevus-Associated Melanoma: Beyond MIA Score Risk Stratification.

Thin Nevus-Associated Melanoma: Beyond MIA Score Risk Stratification.

Journal: Cancers

Published: July 02, 2026

Prognostic value of different metabolic response criteria in patients with advanced melanoma treated with immunotherapy: a comparative analysis of PECRIT, PERCIMT, and EORTC criteria.

Prognostic value of different metabolic response criteria in patients with advanced melanoma treated with immunotherapy: a comparative analysis of PECRIT, PERCIMT, and EORTC criteria.

Journal: European journal of nuclear medicine and molecular imaging

Published: June 26, 2026

PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.

PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.

Journal: JAMA oncology

Published: June 04, 2026

Exploring the Role of TERT Promoter Mutations in Advanced Melanoma Treated With BRAF/MEK Inhibitors or Immune Checkpoint Inhibitors.

Exploring the Role of TERT Promoter Mutations in Advanced Melanoma Treated With BRAF/MEK Inhibitors or Immune Checkpoint Inhibitors.

Journal: Anticancer research

Published: May 12, 2026

Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.

Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 06, 2026

Erratum: Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.

Erratum: Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.

Journal: JCO precision oncology

Published: January 29, 2026

Topical Ruxolitinib for Immune Checkpoint Inhibitor-Induced Vitiligo.

Topical Ruxolitinib for Immune Checkpoint Inhibitor-Induced Vitiligo.

Journal: International journal of dermatology

Published: January 28, 2026

Efficacy of Adding Immune Checkpoint Inhibition to Chemotherapy, With or Without VEGF Inhibition, in Patients With Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis With Reconstructed Individual Patient Data.

Efficacy of Adding Immune Checkpoint Inhibition to Chemotherapy, With or Without VEGF Inhibition, in Patients With Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis With Reconstructed Individual Patient Data.

Journal: JTO clinical and research reports

Published: November 13, 2025

Toward Personalized Response Monitoring in Melanoma Patients Treated with Immunotherapy and Target Therapy.

Toward Personalized Response Monitoring in Melanoma Patients Treated with Immunotherapy and Target Therapy.

Journal: Diagnostics (Basel, Switzerland)

Published: November 05, 2025

Rapid radiological response of leptomeningeal carcinosis and prolonged survival to encorafenib and binimetinib in BRAF-mutated melanoma.

Rapid radiological response of leptomeningeal carcinosis and prolonged survival to encorafenib and binimetinib in BRAF-mutated melanoma.

Journal: Anti-cancer drugs

Published: May 29, 2025

Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data.

Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data.

Journal: Cancers

Published: April 27, 2025

Merkel Cell Carcinoma: An Updated Review Focused on Bone and Bone Marrow Metastases.

Merkel Cell Carcinoma: An Updated Review Focused on Bone and Bone Marrow Metastases.

Journal: Cancers

Published: April 02, 2025

Showing 1-12 of 87

Last Updated: 09/26/2026